SCHEMBL5029381

SCHEMBL5029381

CC(C)N(C)[C@@H]1CC[C@H](N(Cc2ccccc2)Cc2ccccc2)[C@H](CC#N)C1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 5/20 0.38
SLC6A2 P23975 4/20 0.38
RORC P51449 5/20 0.36
CCR2 P41597 2/20 0.34
KCNH2 Q12809 2/20 0.34
CYP2D6 P10635 1/20 0.34
MAOB P27338 1/20 0.34
SLC6A3 Q01959 2/20 0.33
EBP Q15125 1/20 0.33
SLC18A3 Q16572 1/20 0.33
NAAA Q02083 1/20 0.32
TSHR P16473 1/20 0.32
YTHDC1 Q96MU7 1/20 0.32
ADRA2B P18089 1/20 0.31
ADRA2C P18825 1/20 0.31
HTR2A P28223 1/20 0.31
ADRA1A P35348 1/20 0.31
OPRK1 P41145 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5031949 0.81 SLC6A2 (0.38) SLC6A4SLC6A2RORCCCR2KCNH2
SCHEMBL5031820 0.80 CCR2 (0.39) SLC6A4SLC6A2RORCCCR2KCNH2
SCHEMBL5031958 0.78 ALDH1A1 (0.36) SLC6A4SLC6A2RORCMAOBSLC18A3
SCHEMBL5033614 0.72 PTGES (0.38) RORCTSHR
SCHEMBL5033608 0.72 PTGES (0.38) RORCTSHR
SCHEMBL5029318 0.70
SCHEMBL5027120 0.70 CCR2 (0.43) RORCCCR2KCNH2CYP2D6
SCHEMBL5027115 0.70 CCR2 (0.43) RORCCCR2KCNH2CYP2D6
SCHEMBL5027117 0.70 CCR2 (0.43) RORCCCR2KCNH2CYP2D6
SCHEMBL5033782 0.66 CCR2 (0.41) CCR2KCNH2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7378409-B2 Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY (US) 2008-05-27 US disclosed
US-20050054626-A1 Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY 2005-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054626-A1 Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity CCL11, CCR1, CCR2 SLC6A4 1592/4885SLC6A2 2558/4885RORC 1553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.